Reneo Pharmaceuticals, Inc. – NASDAQ:RPHM

Financial Health
0
1
2
3
4
5
6
7
8
9

Reneo Pharmaceuticals stock price monthly change

-14.94%
month

Reneo Pharmaceuticals stock price quarterly change

-14.45%
quarter

Reneo Pharmaceuticals stock price yearly change

-80.29%
year

Reneo Pharmaceuticals key metrics

Market Cap
60.84M
Enterprise value
146.56M
P/E
-3.19
EV/Sales
N/A
EV/EBITDA
-2.82
Price/Sales
N/A
Price/Book
1.65
PEG ratio
-0.05
EPS
-2.17
Revenue
N/A
EBITDA
-77.45M
Income
-70.70M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Reneo Pharmaceuticals stock price history

Reneo Pharmaceuticals stock forecast

Reneo Pharmaceuticals financial statements

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM): Profit margin
Jun 2023 0 -19.53M
Sep 2023 0 -19.19M
Dec 2023 734K -23.55M -3208.99%
Mar 2024 0 -8.42M
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM): Analyst Estimates
Sep 2025 7.96M -10.46M -131.28%
Oct 2025 7.96M -10.34M -129.78%
Dec 2025 15.96M -6.42M -40.22%
Dec 2025 15.96M -6.34M -39.76%
  • Analysts Price target

  • Financials & Ratios estimates

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM): Debt to assets
Jun 2023 148039000 15.51M 10.48%
Sep 2023 130388000 15.44M 11.84%
Dec 2023 107436000 18.82M 17.52%
Mar 2024 84639000 3.39M 4.01%
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM): Cash Flow
Jun 2023 -16.11M -69.01M 63.81M
Sep 2023 -18.76M 21.25M 173K
Dec 2023 -19.75M 39.77M -4.12M
Mar 2024 -21.01M 13.75M 0

Reneo Pharmaceuticals alternative data

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM): Employee count
Aug 2023 48
Sep 2023 51
Oct 2023 51
Nov 2023 51
Dec 2023 55
Jan 2024 55
Feb 2024 55
Mar 2024 55
Apr 2024 55
May 2024 55
Jun 2024 8
Jul 2024 8

Reneo Pharmaceuticals other data

26.18% -41.12%
of RPHM is owned by hedge funds
6.41M -10.07M
shares is hold by hedge funds

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM): Insider trades (number of shares)
Period Buy Sel
Jun 2023 0 100000
Aug 2023 0 15625
May 2024 414281 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
LEONARD BRADEN MICHAEL 10 percent owner
Common Stock 335,000 $1.54 $515,900
Purchase
LEONARD BRADEN MICHAEL 10 percent owner
Common Stock 79,281 $1.56 $123,678
Option
HALL ASHLEY officer: Chief De.. Stock option (right to buy) 15,625 $1.8 $28,125
Option
HALL ASHLEY officer: Chief De.. Common Stock 15,625 $1.8 $28,125
Sale
HALL ASHLEY officer: Chief De.. Common Stock 15,625 $6.28 $98,063
Sale
NOVO HOLDINGS A/S 10 percent owner
Common Stock 100,000 $7.1 $709,700
Purchase
O'DONNELL NIALL director
Common Stock 125,000 $8 $1,000,000
Purchase
CRUSE MICHAEL officer: Chief Operating Officer
Common Stock 7,500 $3.39 $25,448
Purchase
CRUSE MICHAEL officer: Chief Operating Officer
Common Stock 3,212 $3.21 $10,307
Option
GREY MICHAEL G director, officer.. Stock option (right to buy) 50,000 $1.97 $98,500
Friday, 4 October 2024
globenewswire.com
Wednesday, 2 October 2024
globenewswire.com
Tuesday, 3 September 2024
businesswire.com
Tuesday, 13 August 2024
globenewswire.com
Wednesday, 26 June 2024
globenewswire.com
Monday, 24 June 2024
prnewswire.com
Friday, 21 June 2024
globenewswire.com
globenewswire.com
Tuesday, 14 May 2024
businesswire.com
Monday, 13 May 2024
prnewswire.com
prnewswire.com
prnewswire.com
businesswire.com
globenewswire.com
Tuesday, 7 May 2024
globenewswire.com
Thursday, 28 March 2024
globenewswire.com
Friday, 15 December 2023
Zacks Investment Research
Thursday, 2 November 2023
GlobeNewsWire
Sunday, 29 October 2023
Seeking Alpha
Tuesday, 29 August 2023
GlobeNewsWire
Tuesday, 6 September 2022
GlobeNewsWire
Wednesday, 2 February 2022
GlobeNewsWire
Monday, 11 October 2021
GlobeNewsWire
Tuesday, 28 September 2021
GlobeNewsWire
Thursday, 9 September 2021
GlobeNewsWire
  • When is Reneo Pharmaceuticals's next earnings date?

    Unfortunately, Reneo Pharmaceuticals's (RPHM) next earnings date is currently unknown.

  • Does Reneo Pharmaceuticals pay dividends?

    No, Reneo Pharmaceuticals does not pay dividends.

  • How much money does Reneo Pharmaceuticals make?

    Reneo Pharmaceuticals has a market capitalization of 60.84M.

  • What is Reneo Pharmaceuticals's stock symbol?

    Reneo Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "RPHM".

  • What is Reneo Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Reneo Pharmaceuticals?

    Shares of Reneo Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Reneo Pharmaceuticals's key executives?

    Reneo Pharmaceuticals's management team includes the following people:

    • Mr. Gregory J. Flesher Pres, Chief Executive Officer & Director(age: 55, pay: $528,780)
    • Dr. Alejandro Dorenbaum Chief Medical Officer(age: 64, pay: $477,650)
    • Ms. Wendy S. Johnson Consultant(age: 73, pay: $458,400)
  • How many employees does Reneo Pharmaceuticals have?

    As Jul 2024, Reneo Pharmaceuticals employs 8 workers, which is 85% less then previous quarter.

  • When Reneo Pharmaceuticals went public?

    Reneo Pharmaceuticals, Inc. is publicly traded company for more then 4 years since IPO on 8 Apr 2021.

  • What is Reneo Pharmaceuticals's official website?

    The official website for Reneo Pharmaceuticals is reneopharma.com.

  • Where are Reneo Pharmaceuticals's headquarters?

    Reneo Pharmaceuticals is headquartered at 18575 Jamboree Road, Irvine, CA.

  • How can i contact Reneo Pharmaceuticals?

    Reneo Pharmaceuticals's mailing address is 18575 Jamboree Road, Irvine, CA and company can be reached via phone at +61 97333852.

Reneo Pharmaceuticals company profile:

Reneo Pharmaceuticals, Inc.

reneopharma.com
Exchange:

NASDAQ

Full time employees:

8

Industry:

Biotechnology

Sector:

Healthcare

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

18575 Jamboree Road
Irvine, CA 92612

CIK: 0001637715
ISIN: US75974E1038
CUSIP: 75974E103